← Insulin × glycemic control

Observational studyCardiovascular diabetology2015

A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy.

Anselm K Gitt et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 3,810 people · 2015

Not counted

Raised glycemic control

8.3×4.8× to 14×

Bigger than almost all for glycemic control

As reported

OR 8.35, 95% CI 4.84–14.4

Not counted

Raised glycemic control

2.7×1.5× to 4.9×

Bigger than 7 in 10 for glycemic control

As reported

OR 2.70, 95% CI 1.48–4.92

Not counted

Raised glycemic control

4.7×1.7× to 13×

Bigger than 9 in 10 for glycemic control

As reported

OR 4.65, 95% CI 1.68–12.9

Not counted

Raised glycemic control

11×5.9× to 22×

Bigger than almost all for glycemic control

As reported

OR 11.45, 95% CI 5.90–22.2

+1 more in the walkthrough ↓

Five numbers in the abstract

the abstract, start to end

… receiving insulin (Odds Ratio [OR] 8.35; 95% Confidence Interval [CI] 4.84-14.4) and Met/SU (OR 2.70; 95% CI 1.48-4.92) versus …

On the other hand death (OR 4.65; 95% CI 1.68-12.9), MACCE (OR …

… without the need for help (insulin OR 11.45; 95% CI 5.90-22.2 and Met/SU OR …

… in those receiving Met/SU (15.4%; OR 2.70; 95% CI 1.48-4.92) or insulin …

← favours treatmentfavours comparator →
could be chance
Glycemic control
OR 8.354.84–14.4
Glycemic control
OR 2.701.48–4.92
Glycemic control
OR 4.651.68–12.9
Glycemic control
OR 11.455.90–22.2
Glycemic control
OR 2.701.48–4.92
MetforminSulfonylureas & glinidesInsulinGlycemic control
1 / 3

4 papers cite it

2015
2016
2017
2018
2019
2020
2021
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 25645672